Oncology sponsored testing programs 

Invitae partners with biopharma companies to offer sponsored testing for patients who meet eligibility criteria

BRCA Care 

Pfizer has partnered with Invitae to offer the BRCA Care genetic testing program, which provides sponsored, no-charge germline BRCA (gBRCA) testing for patients diagnosed with HER2-negative locally advanced or metastatic breast cancer (HER2- LA/mBC).

Testing for germline BRCA1 or BRCA2 disease-causing variants at diagnosis of locally advanced or metastatic breast cancer may help inform treatment planning. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommend that all patients with recurrent or metastatic breast cancer should be assessed for gBRCA1 and gBRCA2 mutations to identify candidates for PARP-inhibitor therapy.1

Learn more

Detect Hereditary Pancreatic Cancer 

The Detect Hereditary Pancreatic Cancer program provides sponsored, no-charge genetic testing and counseling for individuals diagnosed with pancreatic cancer.

More than 56,000 adult Americans are diagnosed with pancreatic cancer annually and it is the fourth leading cause of cancer death among U.S. adults. The Detect Hereditary Pancreatic Cancer program is designed to identify patients with pancreatic cancer who may be eligible for precision therapies and surgical treatment options based on germline genetic test results.
 

Learn more

Detect Hereditary Prostate Cancer

The Detect Hereditary Prostate Cancer genetic testing program provides sponsored, no-charge genetic testing and counseling for individuals diagnosed with prostate cancer stage II and above.

Prostate cancer is the leading cancer in males. An estimated 174,000 patients are newly diagnosed each year in the U.S. The Detect Hereditary Prostate Cancer program is designed to determine the germline genetic etiology of prostate cancer to evaluate precision medical and surgical treatment options.

Learn more

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed March 6, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.